Opportunistic biotech trading bitch with a focus on nucleic acid-based and -targeted biotech. Fiercely independent. https://t.co/dfLqOuH7Uh
Cite asCryptoQuant has tracked the directional calls on VKTX by @RNAiAnalyst on X since Aug 2025: not yet scored on VKTX (as of Nov 11, 2026).
Other assets covered (14)
2 VKTX calls on record, a thin history.
Relative view by default: fewer than 30 VKTX calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @RNAiAnalyst to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
$NVDA people who say Nvidia has a deep bench and Jensen is replaceable have no idea what they are talking about. Him being at the helm is also deeply important for entire sector, our future actually. And since Trump had known for a year about this, would not exclude possibility that there are many shades of grey to all this.
View original →$PEPG splicing correction accompanied by functional improvement and no cumulative tox. Dare I say home-run data? Come on $ARWR: you can do better with subQ muscle/CNS delivery of MOA like $pepg's. That would be the killer app for DM1.
View original →After $ALNY we'll see the CCO of the next oligoRx stalwart to lose his job.
View original →$ARWR $IONS both companies had told Street to lower its expectations and had been punished for it. But even I did never expect such a horrendous $9M print. Reversion to the mean trade here?
View original →$IONS shocker: just $9M in Q3 sales ofApoc3 trig-lowering ASO. Good/bad for $ARWR? https://t.co/g2yekCVqh1
View original →
